DelveInsight’s, “Adenoid Cystic Carcinoma Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenoid Cystic Carcinoma pipeline landscape. It covers the Adenoid Cystic Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Adenoid Cystic Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Adenoid Cystic Carcinoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Adenoid Cystic Carcinoma Pipeline Outlook

Key Takeaways from the Adenoid Cystic Carcinoma Pipeline Report

• In May 2025, OncoC4 Inc. announced a Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
• DelveInsight’s Adenoid Cystic Carcinoma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Adenoid Cystic Carcinoma treatment.
• The leading Adenoid Cystic Carcinoma Companies such as Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co. and others.
• Promising Adenoid Cystic Carcinoma Pipeline Therapies such as CB-103, Abemaciclib, Lenvatinib, Enfortumab Vedotin, 177Lu-PNT2002, Pembrolizumab, AL101, Regorafenib, Dovitinib (TKI258) and others.

Stay ahead with the most recent pipeline outlook for Adenoid Cystic Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Adenoid Cystic Carcinoma Treatment Drugs

Adenoid Cystic Carcinoma Emerging Drugs Profile

• Rivoceranib : Elevar Therapeutics

Rivoceranib is the first small-molecule tyrosine kinase inhibitor to be approved in gastric cancer under the name Apatinib in China (December 2014). Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), the primary pathway for tumor angiogenesis. VEGFR-2 inhibition is a clinically validated approach to limit tumor growth and disease progression. Rivoceranib has been studied in over 1,000 patients worldwide and was well tolerated in clinical trials with a comparable safety profile to other TKIs. Rivoceranib is currently being studied as a monotherapy and in combination with chemotherapy and immunotherapy. Clinical studies are underway in multiple tumor types including, gastric cancer, hepatocellular carcinoma (combo w/camrelizumab), adenoid cystic carcinoma, and colorectal cancer (combo w/Lonsurf®). Orphan drug designations for rivoceranib have been granted in gastric cancer (U.S., EU, and South Korea) in adenoid cystic carcinoma (U.S.), and hepatocellular carcinoma (U.S.).

• Osugacestat: Ayala Pharmaceuticals

Ayala Pharmaceuticals investigational lead candidate (AL-101) is a novel, injectable, potent and selective small molecule gamma secretase inhibitor (GSI). AL101 is currently being studied in 2 ongoing Phase 2 trials. The ACCURACY trial for the treatment of patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC), and our Phase 2 TENACITY trial for the treatment of patients with recurrent/metastatic triple negative breast cancer (R/M TNBC). The US Food and Drug Administration (FDA) granted Orphan Drug Designation and Fast Track Designation to AL101 for the potential treatment of ACC.

The Adenoid Cystic Carcinoma Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Adenoid Cystic Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adenoid Cystic Carcinoma Treatment.
• Adenoid Cystic Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Adenoid Cystic Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adenoid Cystic Carcinoma market

Explore groundbreaking therapies and clinical trials in the Adenoid Cystic Carcinoma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Adenoid Cystic Carcinoma Drugs

Adenoid Cystic Carcinoma Companies

Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co. and others.

Adenoid Cystic Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Adenoid Cystic Carcinoma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Unveil the future of Adenoid Cystic Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Adenoid Cystic Carcinoma Market Drivers and Barriers

Scope of the Adenoid Cystic Carcinoma Pipeline Report

• Coverage- Global
• Adenoid Cystic Carcinoma Companies- Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co. and others.
• Adenoid Cystic Carcinoma Pipeline Therapies- CB-103, Abemaciclib, Lenvatinib, Enfortumab Vedotin, 177Lu-PNT2002, Pembrolizumab, AL101, Regorafenib, Dovitinib (TKI258) and others.
• Adenoid Cystic Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Adenoid Cystic Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Adenoid Cystic Carcinoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Adenoid Cystic Carcinoma Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Adenoid Cystic Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Adenoid Cystic Carcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. AL101: Ayala Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Adenoid Cystic Carcinoma Key Companies
21. Adenoid Cystic Carcinoma Key Products
22. Adenoid Cystic Carcinoma- Unmet Needs
23. Adenoid Cystic Carcinoma- Market Drivers and Barriers
24. Adenoid Cystic Carcinoma- Future Perspectives and Conclusion
25. Adenoid Cystic Carcinoma Analyst Views
26. Adenoid Cystic Carcinoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/adenoid-cystic-carcinoma-pipeline-insight